European college of neuropsychopharmacology network on the prevention of mental disorders and mental health promotion (ECNP PMD-MHP)

Paolo Fusar-Poli; Michael Bauer; Stefan Borgwardt; Andreas Bechdolf; Christoph U Correll; Kim Q Do; Katharina Domschke; Silvana Galderisi; Lars Vedel Kessing; Nikolaos Koutsouleris; Marie-Odile Krebs; Belinda Lennox; Philip McGuire; Andreas Meyer-Lindenberg; Mark J Millan; Dorien Nieman; Andrea Pfennig; Michael Sand; Allan Whenert; Therese van Amelsvoort; Celso Arango

doi:10.1016/j.euroneuro.2019.09.006

European college of neuropsychopharmacology network on the prevention of mental disorders and mental health promotion (ECNP PMD-MHP)

Eur Neuropsychopharmacol. 2019 Dec;29(12):1301-1311. doi: 10.1016/j.euroneuro.2019.09.006. Epub 2019 Oct 9.

Authors

Paolo Fusar-Poli¹, Michael Bauer², Stefan Borgwardt³, Andreas Bechdolf⁴, Christoph U Correll⁵, Kim Q Do⁶, Katharina Domschke⁷, Silvana Galderisi⁸, Lars Vedel Kessing⁹, Nikolaos Koutsouleris¹⁰, Marie-Odile Krebs¹¹, Belinda Lennox¹², Philip McGuire¹³, Andreas Meyer-Lindenberg¹⁴, Mark J Millan¹⁵, Dorien Nieman¹⁶, Andrea Pfennig², Michael Sand¹⁷, Allan Whenert¹⁸, Therese van Amelsvoort¹⁹, Celso Arango²⁰

Affiliations

¹ Early Psychosis: Interventions and Clinical-detection (EPIC) Lab, Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, 5th Floor PO63, 16 De Crespigny Park, SE5 8AF London, UK; OASIS Service, South London and Maudsley NHS Foundation Trust, London, UK; Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy; National Institute for Health Research, Maudsley Biomedical Research Centre, South London and Maudsley NHS Foundation Trust, London, UK. Electronic address: paolo.fusar-poli@kcl.ac.uk.
² Department of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
³ Department of Psychiatry, University of Basel Hospital, Basel, Switzerland; Department of Psychiatry and Psychotherapy, University of Lübeck, Germany.
⁴ Department of Psychiatry, Psychotherapy and Psychosomatic Medicine with Early Intervention and Recognition Centre (FRITZ), Vivantes Klinikum Am Urban, Charité-Universitätsmedizin, Berlin, Germany; Vivantes Klinikum im Friedrichshain, Department of Psychiatry, Psychotherapy and Psychosomatic Medicine, Charité-Universitätsmedizin, Berlin, Germany; ORYGEN, The National Centre of Excellence in Youth Mental Health, Melbourne, Victoria, Australia; Department of Psychiatry and Psychotherapy, University of Cologne, Cologne, Germany.
⁵ Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, 75-59 263rd Street, Glen Oaks, New York, NY 11004, USA; Department of Psychiatry and Molecular Medicine, The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY 11549, USA; Center for Psychiatric Neuroscience, The Feinstein Institute for Medical Research, Manhasset, NY 11030, USA; Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, Germany.
⁶ Center for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
⁷ Department of Psychiatry and Psychotherapy, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
⁸ Department of Psychiatry, University of Campania L. Vanvitelli, Naples, Italy.
⁹ Copenhagen Affective Disorder Research Center (CADIC), Psychiatric Center Copenhagen, Rigshospitalet, Copenhagen, Denmark.
¹⁰ Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany; Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
¹¹ Centre de Psychiatrie et Neurosciences, Université Paris Descartes, PRES Université Paris Sorbonne Paris Cité, UMR S 894 Paris, France; Laboratoire de Physiopathologie des Maladies Psychiatriques, Centre de Psychiatrie et Neurosciences, INSERM, UMR S1266 Paris, France; CNRS, GDR3557-Institut de Psychiatrie, Paris, France; Faculté de Médecine Paris Descartes, GHU Paris - Sainte-Anne, Service Hospitalo-Universitaire, Paris, France.
¹² Department of Psychiatry, University of Oxford, Warneford Hospital, UK.
¹³ OASIS Service, South London and Maudsley NHS Foundation Trust, London, UK; National Institute for Health Research, Maudsley Biomedical Research Centre, South London and Maudsley NHS Foundation Trust, London, UK; Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
¹⁴ Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
¹⁵ Centre for Therapeutic Innovation in Neuropsychiatry, IDR Servier, Croissy sur Seine, Paris 78290 , France.
¹⁶ Amsterdam University Medical Centers (location AMC), Amsterdam, the Netherlands.
¹⁷ Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, United States.
¹⁸ Department of Psychosis, International Clinical Research, H. Lundbeck A/S, Valby, Denmark.
¹⁹ Maastricht University Medical Center, Department of Psychiatry and Psychology, School for Mental Health and Neuroscience, Maastricht, the Netherlands.
²⁰ Institute of Psychiatry and Mental Health. Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón School of Medicine, Universidad Complutense, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), CIBERSAM, Madrid, Spain.

PMID: 31606303
DOI: 10.1016/j.euroneuro.2019.09.006

Abstract

Prevention is the most promising way to reduce the high personal, familial, societal, clinical and economic costs of mental disorders in Europe and worldwide. A complementary approach is to go beyond the prevention of mental ill health, to promote good mental health. This manuscript highlights the first European consortium fostering cutting-edge multidisciplinary research in these two areas. The ECNP-funded Network on the Prevention of Mental Disorders and Mental Health Promotion (ECNP PMD-MHP) brings together European sites of excellence with different expertise for translational research collaboration, including partnerships with the industry. The ECNP PMD-MHP Network adopts a transdiagnostic, lifespan, clinical staging model which cuts across different mental disorders and different methodologies. The main aims of the ECNP PMD-MHP Network are to facilitate multidisciplinary collaboration, enhance knowledge and data sharing, standardise core assessment and outcome measures, promote clinical research, apply for grant funding, and generate research reports. By supporting collaborative research, the ECNP PMD-MHP Network will be vital for fostering European psychiatry in the field of prevention of mental disorders and promotion of good mental health.

Keywords: Mental disorder; Mental health; Network; Prevention; Promotion; Psychosis.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Congresses as Topic / trends*
Education / methods
Education / trends*
Europe / epidemiology
Health Promotion / methods
Health Promotion / trends*
Humans
Mental Disorders / epidemiology
Mental Disorders / prevention & control*
Mental Disorders / psychology
Mental Health / trends*
Psychopharmacology / methods
Psychopharmacology / trends*